The FDA approved the targeted therapy zenocutuzumab-zbco for certain patients with lung or pancreatic cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri) for the treatment of adult...
As we head into the holiday season, Cancer Research Catalyst has tantalizing teasers in the form of science stocking stuffers straight from our November edition of Editors’ Picks. This month, the editors of the...
Pancreatic cancer surge in younger people has not led to a rise in deaths, and researchers will study long-term survivors to better understand cancer responses.
The FDA granted accelerated approval to the first-in-class HER2-directed bispecific antibody zanidatamab-hrii. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic human epidermal...
The FDA Project Renewal initiative has updated the approved indications for fludarabine phosphate chemotherapy in chronic lymphocytic leukemia. The U.S. Food and Drug Administration (FDA) has approved updated labeling of fludarabine phosphate (Fludarabine Phosphate...
Using high-dose testosterone after prostate cancer stops responding to androgen deprivation therapy can stop tumor growth.
The FDA approved revumenib, a first-in-class menin inhibitor, to treat acute leukemias with a KMT2A translocation. The U.S. Food and Drug Administration (FDA) has approved revumenib (Revuforj) for the treatment of adult and pediatric...
Complications can affect men years after prostate cancer treatment, and many people eligible for lung cancer screening do not get it.
New research into potential causes of gastric cancer is looking beyond H. pylori to other bacteria within the gastric microbiome.
Combination of radiation, chemotherapy, and immunotherapy can shrink tumors and allow surgery, with much better survival rate rather than with non-surgical treatment alone. In some cases of advanced esophageal cancer that are considered to...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More